Tyra Biosciences reports 79% response rate in Phase 2 bladder cancer study of dabogratinib at 60 mg dose

Tyra Biosciences released initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade intermediate-risk NMIBC.

• Data supported meaningful tumor responses, with activity strongest in patients with minimal disease, underpinning a planned adjuvant Phase 3 strategy.
• Safety profile appeared suitable for chronic dosing, with limited severe treatment-related events and no major class-related toxicities highlighted.
• Development plan calls for completing the 60 mg once-daily cohort, starting a 70 mg cohort for higher-burden disease, then aligning Phase 3 design.
• Results were already presented in the release, with a management conference call scheduled today to discuss the findings.